1. Home
  2. ABTS vs CRVO Comparison

ABTS vs CRVO Comparison

Compare ABTS & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABTS
  • CRVO
  • Stock Information
  • Founded
  • ABTS 2010
  • CRVO 2001
  • Country
  • ABTS Hong Kong
  • CRVO United States
  • Employees
  • ABTS N/A
  • CRVO N/A
  • Industry
  • ABTS Computer Software: Programming Data Processing
  • CRVO Biotechnology: Pharmaceutical Preparations
  • Sector
  • ABTS Technology
  • CRVO Health Care
  • Exchange
  • ABTS Nasdaq
  • CRVO Nasdaq
  • Market Cap
  • ABTS 15.9M
  • CRVO 18.2M
  • IPO Year
  • ABTS N/A
  • CRVO N/A
  • Fundamental
  • Price
  • ABTS $3.31
  • CRVO $5.79
  • Analyst Decision
  • ABTS
  • CRVO Strong Buy
  • Analyst Count
  • ABTS 0
  • CRVO 8
  • Target Price
  • ABTS N/A
  • CRVO $23.43
  • AVG Volume (30 Days)
  • ABTS 27.5K
  • CRVO 10.8M
  • Earning Date
  • ABTS 12-31-2024
  • CRVO 05-13-2025
  • Dividend Yield
  • ABTS N/A
  • CRVO N/A
  • EPS Growth
  • ABTS N/A
  • CRVO N/A
  • EPS
  • ABTS N/A
  • CRVO N/A
  • Revenue
  • ABTS $5,343,888.00
  • CRVO $10,066,550.00
  • Revenue This Year
  • ABTS N/A
  • CRVO $34.11
  • Revenue Next Year
  • ABTS N/A
  • CRVO N/A
  • P/E Ratio
  • ABTS N/A
  • CRVO N/A
  • Revenue Growth
  • ABTS 3970.67
  • CRVO 116.29
  • 52 Week Low
  • ABTS $0.25
  • CRVO $1.80
  • 52 Week High
  • ABTS $4.19
  • CRVO $26.38
  • Technical
  • Relative Strength Index (RSI)
  • ABTS 80.04
  • CRVO 83.84
  • Support Level
  • ABTS $3.07
  • CRVO $1.92
  • Resistance Level
  • ABTS $3.74
  • CRVO $2.30
  • Average True Range (ATR)
  • ABTS 0.20
  • CRVO 0.63
  • MACD
  • ABTS 0.37
  • CRVO 0.41
  • Stochastic Oscillator
  • ABTS 77.66
  • CRVO 63.97

About ABTS Abits Group Inc

Abits Group Inc is a digital data center operator with bitcoin self-mining operations.

About CRVO CervoMed Inc.

CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Share on Social Networks: